Axonis Therapeutics Email Formats
Biotechnology Research • 
Boston, Massachusetts, United States • 21-50 Employees
Axonis Therapeutics Email Formats
Axonis Therapeutics uses 4 email formats. The most common is {first initial} (e.g., j@axonis.us), used 33.3% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial} | j@axonis.us | 33.3% |
{first initial}.{last name} | j.doe@axonis.us | 22.2% |
{first name} | john@axonis.us | 22.2% |
{first name}.{last name} | john.doe@axonis.us | 22.2% |
Key Contacts at Axonis Therapeutics
Joanna Stanicka
Chief Executive Officer
Yi Chen
Senior Director, Head Of Neuropharmacology
Megan Johnson
Associate Director, Clinical Operations
Patrick J. Carew
Chief Operating Officer Coo & Board Member Founder
Tiasha Ayumi Shafiq
Director, Chief Of Staff
Mike Wiecek
Senior Director, Finance & Operations
Company overview
| Headquarters | 75 Kneeland St, 14th Floor, Boston, Massachusetts 02111, US |
| Phone number | +16172215364 |
| Website | |
| SIC | 873 |
| Keywords | Biotechnology, Drug Discovery, Neuromodulation, Neuroprotection, Neuroregeneration |
| Founded | 2019 |
| Employees | 21-50 |
| Socials |
About Axonis Therapeutics
Axonis Therapeutics is a Boston-based, neuro-focused biotechnology company developing first- and best-in-class medicines targeting KCC2, the critical mediator of inhibitory neurotransmission within the brain, by translating breakthrough discoveries spun out from Boston Children’s Hospital, Harvard and Laval University. The company has built a proprietary KCC2 discovery engine, based on several years of world-leading know-how, to become the leaders in this potentially blockbuster drug space. Axonis’ lead development candidate, AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for inhibitory neurotransmission, for the treatment of epilepsy and pain. Axonis recently closed a $115 Million Series A financing co-led by Cormorant Asset Management and venBio Partners with significant investments from Sofinnova Investments, MRL Ventures Fund (Merck & Co., Rahway, NJ), Perceptive Advisors, Solasta Ventures and Lumira Ventures. Axonis is grateful for grant awards received from NIH, DoD, Wings for Life, MLSC, Praxis SCI, CURE Epilepsy, ISSNL and SynGAP Foundation. The company is headquartered in Boston, MA. For more information, visit www.axonis.us.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Axonis Therapeutics has 9 employees across 6 departments.
Departments
Number of employees
Funding Data
Explore Axonis Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
Axonis Therapeutics Tech Stack
Discover the technologies and tools that power Axonis Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Security
WordPress themes
JavaScript libraries
Page builders
JavaScript libraries
CDN
JavaScript libraries
Miscellaneous
Programming languages
Blogs
SEO
Frequently asked questions
4.8
40,000 users
